Sarcoïdose: verandering in therapeutische inzichten

Lieke S J Kamphuis; Jan A M van Laar; Robert W A M Kuijpers; Tom Missotten; H. Bing Thio; P Martin van Hagen

Sarcoïdose: verandering in therapeutische inzichten

Translated title of the contribution: Sarcoidosis: changing insights in therapy

Lieke S J Kamphuis
, Jan A M van Laar
, Robert W A M Kuijpers
, Tom Missotten
, H. Bing Thio
, P Martin van Hagen^*

^*Corresponding author for this work

The Rotterdam Eye Hospital

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Sarcoidosis is a granulomatous disease of unknown etiology.

Standard treatment with immune suppressants such as glucocorticoids is started when vital organ function is threatened.

Biotechnology has resulted in new treatments ('biologicals'), in particular monoclonal antibodies, that may be effective in the treatment of sarcoidosis.

In patients with sarcoidosis, only the use of monoclonal antibodies that block tumour necrosis factor (TNF) has been studied scientifically, other biologicals hardly at all.

TNF-blockers are used at present in patients with therapy refractory sarcoidosis.

Translated title of the contribution	Sarcoidosis: changing insights in therapy
Original language	Dutch
Pages (from-to)	2189-2194
Number of pages	6
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	154
Issue number	47
Publication status	Published - 14 Oct 2010

Research programs

EMC MM-02-72-02
EMC MM-03-61-05-A

Access to Document

https://www.ntvg.nl/artikelen/sarcoidose-verandering-therapeutische-inzichten

Cite this

@article{3eb45767e96b4a1bb776a59bc4df1e72,

title = "Sarco{\"i}dose: verandering in therapeutische inzichten",

abstract = "Sarcoidosis is a granulomatous disease of unknown etiology. Standard treatment with immune suppressants such as glucocorticoids is started when vital organ function is threatened. Biotechnology has resulted in new treatments ('biologicals'), in particular monoclonal antibodies, that may be effective in the treatment of sarcoidosis. In patients with sarcoidosis, only the use of monoclonal antibodies that block tumour necrosis factor (TNF) has been studied scientifically, other biologicals hardly at all. TNF-blockers are used at present in patients with therapy refractory sarcoidosis.",

author = "Kamphuis, \{Lieke S J\} and \{van Laar\}, \{Jan A M\} and Kuijpers, \{Robert W A M\} and Tom Missotten and Thio, \{H. Bing\} and \{van Hagen\}, \{P Martin\}",

year = "2010",

month = oct,

day = "14",

language = "Dutch",

volume = "154",

pages = "2189--2194",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "47",

}

TY - JOUR

T1 - Sarcoïdose: verandering in therapeutische inzichten

AU - Kamphuis, Lieke S J

AU - van Laar, Jan A M

AU - Kuijpers, Robert W A M

AU - Missotten, Tom

AU - Thio, H. Bing

AU - van Hagen, P Martin

PY - 2010/10/14

Y1 - 2010/10/14

N2 - Sarcoidosis is a granulomatous disease of unknown etiology. Standard treatment with immune suppressants such as glucocorticoids is started when vital organ function is threatened. Biotechnology has resulted in new treatments ('biologicals'), in particular monoclonal antibodies, that may be effective in the treatment of sarcoidosis. In patients with sarcoidosis, only the use of monoclonal antibodies that block tumour necrosis factor (TNF) has been studied scientifically, other biologicals hardly at all. TNF-blockers are used at present in patients with therapy refractory sarcoidosis.

AB - Sarcoidosis is a granulomatous disease of unknown etiology. Standard treatment with immune suppressants such as glucocorticoids is started when vital organ function is threatened. Biotechnology has resulted in new treatments ('biologicals'), in particular monoclonal antibodies, that may be effective in the treatment of sarcoidosis. In patients with sarcoidosis, only the use of monoclonal antibodies that block tumour necrosis factor (TNF) has been studied scientifically, other biologicals hardly at all. TNF-blockers are used at present in patients with therapy refractory sarcoidosis.

UR - https://www.scopus.com/pages/publications/79959539465

M3 - Article

C2 - 21118599

SN - 0028-2162

VL - 154

SP - 2189

EP - 2194

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 47

ER -

Sarcoïdose: verandering in therapeutische inzichten

Abstract

Research programs

Access to Document

Other files and links

Fingerprint

Cite this